Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
about
Towards Stratified Medicine in Plasma Cell MyelomaSecond-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.Novel investigational drugs active as single agents in multiple myeloma.Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.Immunoproteasome inhibition and bioactivity of thiasyrbactins.
P2860
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Marizomib irreversibly inhibit ...... oma and solid tumour patients.
@en
type
label
Marizomib irreversibly inhibit ...... oma and solid tumour patients.
@en
prefLabel
Marizomib irreversibly inhibit ...... oma and solid tumour patients.
@en
P2093
P2860
P50
P356
P1476
Marizomib irreversibly inhibit ...... loma and solid tumour patients
@en
P2093
Andrew Spencer
Dharminder Chauhan
Francis J Burrows
Mohit Trikha
Nancy Levin
Steven D Reich
P2860
P304
P356
10.1111/BJH.14113
P407
P577
2016-05-09T00:00:00Z